Abstract: A pyrimidine compound of the formula [I] ##STR1## wherein R1 is H, C.sub.1 -C.sub.4 lower alkyl, halogen atom, --OH, C.sub.1 -C.sub.4 lower alkoxy, C.sub.1 -C.sub.6 hydroxy(lower)alkoxy or --NH.sub.2 ; R2 is H, --NH.sub.2 or --NHCOCH.sub.3 ; R3 is --NR5(CH.sub.2)i--CH.sub.2 OH; R4 is H, halogen atom, --NH.sub.2, --CN, --CHO, --CH.sub.2 OH, --COOH, --CH.sub.2 NH.sub.2, --CONH.sub.2 or --CH.dbd.N--A wherein A is --OH, C.sub.1 -C.sub.4 lower alkyl or C.sub.1 -C.sub.4 lower alkoxy; R5 is H or C.sub.1 -C.sub.4 lower alkyl; and i is an integer of 1 to 4, and an anti-rotavirus agent comprising, as an active ingredient, a compound of the formula [I] wherein R3 is a group selected from the following: ##STR2## The novel pyrimidine compound of the present invention and related derivatives thereof have superior anti-rotavirus action and are useful for the prophylaxis and treatment of rotaviral diseases.

Abstract: A method for determining fibrinogen concentration whereby thrombin or a protease inhibitor having similar activity thereto is added to an undiluted to test sample to convert fibrinogen in the sample to fibrin, and determining a coagulation time fibrinogen is converted in a reaction mixture containing a salt at a high concentration and a reagent therefor. The determination in the presence of a salt at a high concentration permits simplified determination without diluting the test sample.

Abstract: An improved method of a conventional antithrombin III activity determination method, which does not require dilution of a sample and can avoid influence of heparin cofactor II is provided. This method is characterized in that the reaction of a sample with thrombin in the presence of heparin is carried out in the presence of more than 0.2 to 0.9M of a salt, while such a reaction is carried out in the presence of 0.2M of a salt in a conventional method.

Abstract: An accurate, rapid and simple method of determining blood coagulation factor XIII activity and a kit of reagents therefor are provided. A sample and a fibrin precipitation inhibitor are mixed, or a sample, fibrinogen and a fibrin precipitation inhibitor are mixed; a thrombin solution is added; the fibrin coagulation time is measured in the presence of calcium ion; and the coagulation time is compared with the normal coagulation time. The kit for the determination comprises thrombin, calcium ion and a fibrin precipitation inhibitor, and may be combined with fibrinogen.

Abstract: The surfactant composition of the present invention, which comprises mono acyl glycero phosphilipid(s) and one or more compounds selected from the group consisting of polyglycerol fatty acid esters, sucrose fatty acid esters, sorbitan fitty acid esters and glycerol fatty acid monoesters as essential components, exhibits excellent acid- and salt-resistances, permeability, emulsification and dispersion capabilities and hydrophilicity. Further it is highly safe and can be appropriately applied to various products, in particular, food, cosmetics and pharamceuticals.

Abstract: Reagent for the measurement of direct bilirubin comprising a buffer solution having a pH range of 3.5 to 4.5 which contains bilirubin oxidase, preferably in the form of a test kit consisting essentially of (i) a buffer solution having a pH range of 3.5 to 4.5, (ii-a) a lyophilized bilirubin oxidase, (ii-b) a buffer solution for dissolving the lyophilized bilirubin oxidase, and (iii) a standard serum containing a prescribed amount of bilirubin, and a method for measurement of direct bilirubin by using the reagent. The reagent and method are useful for diagnosis of various diseases, for example, various hepatic diseases (e.g. jaundice) and cholepathia.

Abstract: A therapeutic agent for treating consciousness disorder and perception and movement which comprises as an essential active ingredient a phosphatidic acid derivative selected from a phosphatidylcholine, a phosphatidic acid and a phosphatidylethanolamine in admixture with a conventional carrier. Said agent is administered to the patient suffered from consciousness disorder and perception and movement disorder, particularly the post-traumatic syndrome of the head injury and the sequelae of apoplexy or whiplash injury in oral or parenteral route, preferably in an intravenous route.

Abstract: Improved process for preparing 1,2-diacyl-3-glycerylphosphorylcholines, wherein the diacyl groups are, different or the same, a residue of a saturated or unsaturated fatty acid, particularly one of the acyl groups being a residue of a highly unsaturated fatty acid or being a residue of a saturated or unsaturated fatty acid labelled with an isotope, which comprises acylating a glyceryl-phosphorylcholine or monoacyl derivative thereof or the salt thereof with an acylating agent (e.g. 1-acylimidazole or 4-acyl-3-phenyl-1,2,4-oxadiazol-5-one) in the presence of a catalyst (e.g. an alkali salt of a nitrogen-containing 5-membered heterocyclic compound or sodium oxide).

Abstract: Glycosides having an excellent sweetness and hydrolysate thereof of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are each hydrogen, a residue of .beta.-D-glucose, or a residue of an oligosaccharide comprising not more than four D-glucose having 1,2-, 1,4- and/or 1,6-bond, provided that the total number of D-glucose residue in R.sub.1 and R.sub.2 is not more than 6, which is isolated from a fruit of a plant of Cucurbitaceae, particularly Momordica grosvenori Swingle (e.g. Fructus Momordicae) and said hydrolysates are produced by hydrolyzing the glycosides with an enzyme.